{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":9.490897,"similar":[{"pmid":32482373,"title":"Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","text":["Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.","Arch Med Res","Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib","32482373"],"abstract":["Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab."],"journal":"Arch Med Res","authors":["Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.arcmed.2020.05.009","keywords":["covid-19","cytokine storm syndrome","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532114882035712,"score":338.8505},{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490384941057,"score":269.20584},{"pmid":32337664,"title":"Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.","text":["Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.","Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and \"Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)\" in China, so as to provide reference for the treatment of COVID-19.","Clin Drug Investig","Zhang, Shengyu","Li, Lei","Shen, Aizong","Chen, Yongwu","Qi, Zhigang","32337664"],"abstract":["Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and \"Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)\" in China, so as to provide reference for the treatment of COVID-19."],"journal":"Clin Drug Investig","authors":["Zhang, Shengyu","Li, Lei","Shen, Aizong","Chen, Yongwu","Qi, Zhigang"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337664","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s40261-020-00917-3","locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494153523202,"score":264.89114},{"pmid":32378647,"title":"Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","text":["Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.","Drug Discov Ther","Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing","32378647"],"abstract":["The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated."],"journal":"Drug Discov Ther","authors":["Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378647","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.5582/ddt.2020.03006","keywords":["coronavirus","cytokine storm","pneumonia","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097302917120,"score":264.3774},{"pmid":32441764,"title":"Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","text":["Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken.","Br J Pharmacol","Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter","32441764"],"abstract":["Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken."],"journal":"Br J Pharmacol","authors":["Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441764","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15137","keywords":["ards","artd","adalimumab","anakinra","covid-19","il6","nad+","parp","parp inhibitor","sars-cov-2","sarilumab","siltuximab","tocilizumab","apoptosis","chloroquine","cytokine release syndrome","hydroxychloroquine","lopinavir","lung fibrosis","macrodomain","macrophage overactivation syndrome","mechanical ventilation","nicotinamide-riboside","olaparib","remedsivir","ritonavir","rucaparib","talazoparib"],"locations":["Siltuximab"],"e_drugs":["tocilizumab","siltuximab","sarilumab","Adalimumab","canakinumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119436480512,"score":227.84921}]}